| 1 | Curr Opin Investig Drugs 2002 Jul 3: 1073-80 |
|---|---|
| PMID | 12186270 |
| Title | New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update. |
| Abstract | The so-called atypical antipsychotics undergo extensive metabolism, except for amisulpride, which is substantially excreted unchanged. Risperidone is oxidized by CYP2D6/CYP3A4 and iloperidone is reduced by cytosolic enzymes, although CYP1A2, CYP2E1 and CYP3A4 are involved as well. Olanzapine is both conjugated and oxidized (mainly by CYP1A2), while quetiapine and zotepine primarily undergo CYP3A4-mediated oxidation. Ziprasidone pathways include aldehyde oxidase-mediated reduction and CYP3A4-mediated oxidation. The main metabolites of risperidone, zotepine and possibly perospirone and ziprasidone contribute to the parent drug's effect. Information is limited, however, on some promising antipsychotics in the pipeline. |
| SCZ Keywords | schizophrenia |
| 2 | PLoS ONE 2012 -1 7: e34809 |
| PMID | 22606226 |
| Title | Genetic polymorphisms in CYP2E1: association with schizophrenia susceptibility and risperidone response in the Chinese Han population. |
| Abstract | CYP2E1 is a member of the cytochrome P450 superfamily, which is involved in the metabolism and activation of both endobiotics and xenobiotics. The genetic polymorphisms of CYP2E1 gene (Chromosome 10q26.3, Accession Number NC_000010.10) are reported to be related to the development of several mental diseases and to be involved in the clinical efficacy of some psychiatric medications. We investigated the possible association of CYP2E1 polymorphisms with susceptibility to schizophrenia in the Chinese Han Population as well as the relationship with response to risperidone in schizophrenia patients. In a case-control study, we identified 11 polymorphisms in the 5' flanking region of CYP2E1 in 228 schizophrenia patients and 384 healthy controls of Chinese Han origin. From among the cases, we chose 130 patients who had undergone 8 weeks of risperidone monotherapy to examine the relationship between their response to risperidone and CYP2E1 polymorphisms. Clinical efficacy was assessed using the Brief Psychiatric Rating Scale (BPRS). Statistically significant differences in allele or genotype frequencies were found between cases and controls at rs8192766 (genotype p?=?0.0048, permutation p?=?0.0483) and rs2070673 (allele: p?=?0.0018, permutation p?=?0.0199, OR?=?1.4528 95%CI?=?1.1487-1.8374; genotype: p?=?0.0020, permutation p?=?0.0225). In addition, a GTCAC haplotype containing 5 SNPs (rs3813867, rs2031920, rs2031921, rs3813870 and rs2031922) was observed to be significantly associated with schizophrenia (p?=?7.47E-12, permutation p<0.0001). However, no association was found between CYP2E1 polymorphisms/haplotypes and risperidone response. Our results suggest that CYP2E1 may be a potential risk gene for schizophrenia in the Chinese Han population. However, polymorphisms of the CYP2E1 gene may not contribute significantly to individual differences in the therapeutic efficacy of risperidone. Further studies in larger groups are warranted to confirm our results. |
| SCZ Keywords | schizophrenia |